{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:09:37Z","timestamp":1794002977537,"version":"4.8.0"},"reference-count":140,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced combination treatment (ACT)\u2014the combination of two advanced agents such as biologics or small molecules\u2014has emerged as a promising strategy in the management of inflammatory bowel disease refractory to conventional treatment, with severe extraintestinal manifestations, or with coexisting immune-mediated inflammatory diseases. ACT including complementary mechanisms of action aims to overcome the therapeutic ceiling observed with monotherapy. Its rationale is supported by preclinical and mechanistic data demonstrating synergistic immunological effects when distinct inflammatory pathways are targeted simultaneously. Although observational studies report pooled clinical and endoscopic remission rates of approximately 60% and 30%, respectively, the quality of evidence remains very limited. Most studies are retrospective, heterogeneous in patient populations and treatment regimens, and often report outcomes in aggregate, precluding firm conclusions regarding the efficacy of specific drug combinations. The two and only randomized controlled trials available to date have shown acceptable safety profiles but limited or no clear superiority of ACT over monotherapy. Safety data are reassuring, with no significant increase in serious adverse events. The optimal duration of ACT remains uncertain; while de-escalation to monotherapy following deep remission is feasible in selected patients, relapse rates vary, emphasizing the need for individualized treatment decisions and long-term follow-up. High treatment costs also pose a barrier to widespread adoption of ACT, though biosimilars may help offset these concerns. In summary, ACT may represent a potentially valuable therapeutic option in selected high-risk or treatment-resistant patients with inflammatory bowel disease; however, its true clinical benefit remains uncertain and requires confirmation through robust, well-powered randomized controlled trials.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaf161","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:43:12Z","timestamp":1756813392000},"source":"Crossref","is-referenced-by-count":20,"title":["Combination therapy with biologics and\/or small molecules in inflammatory bowel disease: a comprehensive review"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P","family":"Gisbert","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM) , Madrid,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4242","authenticated-orcid":false,"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM) , Madrid,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2025102819160075900_jjaf161-B1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025102819160075900_jjaf161-B2","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1007\/s10620-020-06424-x","article-title":"Extraintestinal manifestations in patients with inflammatory bowel disease: study based on the ENEIDA Registry","volume":"66","author":"Algaba","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2025102819160075900_jjaf161-B3","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)?","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"key":"2025102819160075900_jjaf161-B4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/jcm11041076","article-title":"Selecting the best combined biological therapy for refractory inflammatory bowel disease patients","volume":"11","author":"Mas","year":"2022","journal-title":"J Clin Med"},{"key":"2025102819160075900_jjaf161-B5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S2468-1253(23)00008-0","article-title":"Combination biologic therapy for ulcerative colitis","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B6","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3748\/wjg.v30.i15.2068","article-title":"Combination treatment of inflammatory bowel disease: Present status and future perspectives","volume":"30","author":"Triantafillidis","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2025102819160075900_jjaf161-B7","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2025102819160075900_jjaf161-B8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"2025102819160075900_jjaf161-B9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B10","doi-asserted-by":"crossref","first-page":"109545","DOI":"10.1016\/j.intimp.2022.109545","article-title":"Combination therapy in inflammatory bowel disease: Current evidence and perspectives","volume":"114","author":"Dai","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025102819160075900_jjaf161-B11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/ibd\/izae189","article-title":"Combined advanced targeted therapy in inflammatory bowel diseases: an extensive update","volume":"31","author":"Cornet","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"2025102819160075900_jjaf161-B13","first-page":"549","article-title":"Combining biologic agents in inflammatory bowel disease","volume":"15","author":"Abreu","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025102819160075900_jjaf161-B14","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gtc.2021.12.005","article-title":"Dual advanced therapies and novel pharmacotherapies for moderately to severely active Crohn\u2019s disease","volume":"51","author":"Tse","year":"2022","journal-title":"Gastroenterol Clin North Am"},{"key":"2025102819160075900_jjaf161-B16","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025102819160075900_jjaf161-B17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jcag\/gwad032","article-title":"Current evidence for combined targeted therapy for the treatment of inflammatory bowel disease","volume":"7","author":"Wetwittayakhlang","year":"2024","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025102819160075900_jjaf161-B18","doi-asserted-by":"crossref","first-page":"17562848241272995","DOI":"10.1177\/17562848241272995","article-title":"Advanced combination therapy: is it the best way to break the therapeutic ceiling?","volume":"17","author":"Wetwittayakhlang","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"2025102819160075900_jjaf161-B19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cgh.2024.05.051","article-title":"IBD Matchmaking: rational combination therapy","volume":"23","author":"Battat","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B20","first-page":"1","article-title":"Progressing advanced therapies for inflammatory bowel disease: Current status including dual biologic therapy and discontinuation of biologics","author":"Yashima","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B22","doi-asserted-by":"crossref","first-page":"114174","DOI":"10.1016\/j.biopha.2022.114174","article-title":"Breaking through the therapeutic ceiling of inflammatory bowel disease: Dual-targeted therapies","volume":"158","author":"Feng","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2025102819160075900_jjaf161-B23","first-page":"13","article-title":"Immune-mediated inflammatory diseases awareness and management among physicians treating patients with inflammatory bowel disease: an IG-IBD survey","volume":"13","author":"Vernero","year":"2024","journal-title":"J Clin Med"},{"key":"2025102819160075900_jjaf161-B24","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B25","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1136\/gutjnl-2022-327025","article-title":"The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)","volume":"71","author":"Danese","year":"2022","journal-title":"Gut"},{"key":"2025102819160075900_jjaf161-B26","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1177\/10600280221135177","article-title":"Review of dual biologics in specialty pharmacy practice","volume":"57","author":"Quiroga","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2025102819160075900_jjaf161-B27","doi-asserted-by":"crossref","first-page":"103331","DOI":"10.1016\/j.jaut.2024.103331","article-title":"Efficacy and safety of advanced combination treatment in immune-mediated inflammatory disease: a systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Solitano","year":"2024","journal-title":"J Autoimmun"},{"key":"2025102819160075900_jjaf161-B28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000001033","article-title":"A practical guide to combination advanced therapy in inflammatory bowel disease","volume":"40","author":"Ray","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"2025102819160075900_jjaf161-B29","doi-asserted-by":"crossref","first-page":"i348","DOI":"10.1093\/ecco-jcc\/jjab232.455","article-title":"In silico evaluation and pre-clinical efficacy of anti-TNF and anti-IL-23 combination therapy in Inflammatory Bowel Disease","volume":"16","author":"Perrigoue","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025102819160075900_jjaf161-B30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fimmu.2019.00459","article-title":"Combined IL-2 immunocomplex and anti-IL-5 mAb treatment expands Foxp3(+) Treg cells in the absence of eosinophilia and ameliorates experimental colitis","volume":"10","author":"Abo","year":"2019","journal-title":"Front Immunol"},{"key":"2025102819160075900_jjaf161-B31","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/MIB.0b013e318286fa1c","article-title":"TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis","volume":"19","author":"Wedebye Schmidt","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B32","first-page":"133","article-title":"Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis","volume":"50","author":"Hu","year":"2023","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2025102819160075900_jjaf161-B33","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 Blockade in anti-TNF refractory IBD: from mechanisms to clinical reality","volume":"16","author":"Atreya","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025102819160075900_jjaf161-B34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"2025102819160075900_jjaf161-B35","first-page":"8","article-title":"Differential and combinatorial mechanism of action of golimumab and guselkumab in ulcerative colitis induction therapy: il-23 blockade drives restoration of normal epithelium and mucosal healing","volume":"10","author":"Desai","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"2025102819160075900_jjaf161-B36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MIB.0b013e31828100a4","article-title":"Effect of tumor necrosis factor-alpha blockade on mucosal addressin cell-adhesion molecule-1 in Crohn\u2019s disease","volume":"19","author":"Biancheri","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B37","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"2025102819160075900_jjaf161-B38","doi-asserted-by":"crossref","first-page":"100381","DOI":"10.1016\/j.xcrm.2021.100381","article-title":"Dual targeting of lymphocyte homing and retention through \u03b14\u03b27 and \u03b1E\u03b27 inhibition in inflammatory bowel disease","volume":"2","author":"Dai","year":"2021","journal-title":"Cell Rep Med"},{"key":"2025102819160075900_jjaf161-B39","doi-asserted-by":"crossref","first-page":"17562848241309871","DOI":"10.1177\/17562848241309871","article-title":"Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions","volume":"18","author":"Fabisiak","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2025102819160075900_jjaf161-B40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.cgh.2023.11.025","article-title":"EXPLORing the therapeutic ceiling in Crohn\u2019s disease: will combination pave the way?","volume":"22","author":"Torres","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B42","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a European retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2025102819160075900_jjaf161-B43","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819160075900_jjaf161-B44","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/diseases10040102","article-title":"Effectiveness of dual biologic or small molecule therapy for achieving endoscopic remission in refractory inflammatory bowel disease","volume":"10","author":"Abdullah","year":"2022","journal-title":"Diseases"},{"key":"2025102819160075900_jjaf161-B45","doi-asserted-by":"crossref","first-page":"17562848211006669","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025102819160075900_jjaf161-B46","first-page":"406","article-title":"Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature","volume":"17","author":"Gold","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025102819160075900_jjaf161-B47","doi-asserted-by":"crossref","first-page":"102832","DOI":"10.1016\/j.autrev.2021.102832","article-title":"Combination therapy in inflammatory bowel disease\u2014from traditional immunosuppressors towards the new paradigm of dual targeted therapy","volume":"20","author":"Privitera","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2025102819160075900_jjaf161-B48","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/1744666X.2022.2104713","article-title":"Could small molecules be used in combination with biologics for inflammatory bowel disease?","volume":"18","author":"D'Amico","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2025102819160075900_jjaf161-B49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B50","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/cpt.3235","article-title":"Combination therapy with guselkumab and golimumab in patients with moderately to severely active ulcerative colitis: pharmacokinetics, immunogenicity and drug-drug interactions","volume":"115","author":"Shao","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2025102819160075900_jjaf161-B51","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B52","doi-asserted-by":"crossref","first-page":"e15743","DOI":"10.1111\/dth.15743","article-title":"Successful treatment of hidradenitis suppurativa and Crohn\u2019s disease with combined guselkumab and apremilast","volume":"35","author":"Agud-Dios","year":"2022","journal-title":"Dermatol Ther"},{"key":"2025102819160075900_jjaf161-B53","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/ibd\/izab112","article-title":"Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases","volume":"27","author":"Alayo","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.14185","article-title":"Combination treatment with monoclonal antibodies: dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease","volume":"65","author":"Alegre-Bailo","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2025102819160075900_jjaf161-B55","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.12998\/wjcc.v10.i8.2569","article-title":"Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn\u2019s disease: a case report and review of literature","volume":"10","author":"Au","year":"2022","journal-title":"World J Clin Cases"},{"key":"2025102819160075900_jjaf161-B56","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.cgh.2020.08.023","article-title":"Reply","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B57","doi-asserted-by":"crossref","first-page":"e000127","DOI":"10.1136\/bmjgast-2016-000127","article-title":"Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis","volume":"4","author":"Bethge","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"2025102819160075900_jjaf161-B58","first-page":"766","article-title":"Upadacitinib and ustekinumab combination treatment for a refractory case of spondyloarthritis and Crohn\u2019s disease","volume":"42","author":"Bianchi","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2025102819160075900_jjaf161-B59","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/MEG.0000000000001919","article-title":"Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab","volume":"32","author":"Biscaglia","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B60","article-title":"Combination treatment risankizumab and subcutaneous infliximab for refractory Crohn\u2019s disease","author":"Buendia Carcedo","year":"2025","journal-title":"Rev Esp Enferm Dig"},{"key":"2025102819160075900_jjaf161-B61","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ibd\/izx110","article-title":"Combining anti-TNF-alpha and vedolizumab in the treatment of inflammatory bowel disease: a case series","volume":"24","author":"Buer","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B62","article-title":"Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab","volume":"25","author":"Cline","year":"2019","journal-title":"Dermatol Online J"},{"key":"2025102819160075900_jjaf161-B63","first-page":"577","article-title":"A case of dual-targeted therapy for pediatric refractory inflammatory bowel disease","volume":"62","author":"Dai","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"2025102819160075900_jjaf161-B64","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B65","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/00365521.2022.2045350","article-title":"Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study","volume":"57","author":"Eronen","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"2025102819160075900_jjaf161-B66","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.12998\/wjcc.v12.i23.5441","article-title":"Rare extraintestinal manifestations of ulcerative colitis treated with dual biologic therapy: a case report","volume":"12","author":"Filipiuk","year":"2024","journal-title":"World J Clin Cases"},{"key":"2025102819160075900_jjaf161-B67","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/ajg.2017.242","article-title":"Long-term combination therapy with anti-TNF plus vedolizumab induces and maintains remission in therapy-refractory ulcerative colitis","volume":"112","author":"Fischer","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2025102819160075900_jjaf161-B68","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/apt.15891","article-title":"Letter: Combination of biologics in inflammatory bowel diseases","volume":"52","author":"Fumery","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819160075900_jjaf161-B69","doi-asserted-by":"crossref","first-page":"502213","DOI":"10.1016\/j.gastrohep.2024.502213","article-title":"Combined biologic treatment in patient with chronic spontaneous urticaria and Crohn\u2019s disease","volume":"48","author":"Garc\u00eda Mart\u00ednez","year":"2025","journal-title":"Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B70","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cgh.2020.07.046","article-title":"Tofacitinib is safe and effective when used in combination with infliximab for the management of refractory ulcerative colitis","volume":"19","author":"Gilmore","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B71","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"key":"2025102819160075900_jjaf161-B72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.dld.2022.07.012","article-title":"Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study","volume":"55","author":"Guillo","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2025102819160075900_jjaf161-B73","article-title":"Dual biologic or small molecule therapy in pediatric inflammatory bowel disease: a single center experience","volume":"12","author":"Guo","year":"2025","journal-title":"Children (Basel)"},{"key":"2025102819160075900_jjaf161-B74","doi-asserted-by":"crossref","first-page":"otae080","DOI":"10.1093\/crocol\/otae080","article-title":"Dual biologic therapy induces remission in refractory Crohn\u2019s disease with vedolizumab and ustekinumab","volume":"7","author":"Hassan","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"2025102819160075900_jjaf161-B75","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1093\/ibd\/izab095","article-title":"Combined targeted treatment using biologic-tofacitinib co-therapy in chronic active ulcerative colitis","volume":"27","author":"Hilley","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B76","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/ajg.2015.355","article-title":"Vedolizumab and infliximab combination therapy in the treatment of Crohn\u2019s disease","volume":"110","author":"Hirten","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025102819160075900_jjaf161-B77","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MEG.0000000000002203","article-title":"Dual biologic therapy with vedolizumab and ustekinumab for refractory Crohn\u2019s disease in children","volume":"34","author":"Howard","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B78","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaad.2024.03.007","article-title":"Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease","volume":"91","author":"Hren","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025102819160075900_jjaf161-B79","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1097\/PG9.0000000000000225","article-title":"Dual biologic therapy in a patient with Niemann-Pick type C and Crohn disease: a case report and literature review","volume":"3","author":"Hudson","year":"2022","journal-title":"JPGN Rep"},{"key":"2025102819160075900_jjaf161-B80","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1097\/MIB.0000000000001232","article-title":"Efficacy of combination vedolizumab and ustekinumab for refractory Crohn\u2019s disease","volume":"23","author":"Huff-Hardy","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/mrcr\/rxad031","article-title":"Successful treatment of refractory enteritis and arthritis with combination of tumour necrosis factor and interleukin-6 inhibition in patients with ulcerative colitis","volume":"8","author":"Ishigaki","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025102819160075900_jjaf161-B82","doi-asserted-by":"crossref","first-page":"17562848241307598","DOI":"10.1177\/17562848241307598","article-title":"Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China","volume":"18","author":"Jin","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2025102819160075900_jjaf161-B83","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/ibd\/izab028","article-title":"Combining therapies in inflammatory bowel disease: end of the line or a new era?","volume":"27","author":"Judge","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B84","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1007\/s10620-024-08379-9","article-title":"Real-world outcomes of dual advanced therapy in children and young adults with inflammatory bowel disease","volume":"69","author":"Kellar","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2025102819160075900_jjaf161-B85","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2020.02.017","article-title":"Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center","volume":"19","author":"Kwapisz","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B86","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B87","doi-asserted-by":"crossref","first-page":"e01203","DOI":"10.14309\/crj.0000000000001203","article-title":"Dual biologic therapy for refractory Crohn\u2019s disease with perforation in a patient declining surgical intervention","volume":"10","author":"Le","year":"2023","journal-title":"ACG Case Rep J"},{"key":"2025102819160075900_jjaf161-B88","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ibd\/izab176","article-title":"Safety and efficacy of tofacitinib in combination with biologic therapy for refractory Crohn\u2019s disease","volume":"28","author":"Lee","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B89","first-page":"S107","article-title":"Dual biological therapy for ulcerative colitis with intractable pyoderma gangrenosum","volume":"35","author":"Lee","year":"2023","journal-title":"Ann Dermatol"},{"key":"2025102819160075900_jjaf161-B90","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/imj.16120","article-title":"Combination non tumour necrosis factor biologic and small-molecule therapy in a patient with ankylosing spondylitis and Crohn disease","volume":"53","author":"Li","year":"2023","journal-title":"Intern Med J"},{"key":"2025102819160075900_jjaf161-B91","doi-asserted-by":"crossref","first-page":"5264216","DOI":"10.1155\/2017\/5264216","article-title":"Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn\u2019s disease","volume":"2017","author":"Liu","year":"2017","journal-title":"Case Rep Med"},{"key":"2025102819160075900_jjaf161-B92","doi-asserted-by":"crossref","first-page":"otab030","DOI":"10.1093\/crocol\/otab030","article-title":"Favorable outcomes combining vedolizumab with other biologics or tofacitinib for treatment of inflammatory bowel disease","volume":"3","author":"Llano","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2025102819160075900_jjaf161-B93","doi-asserted-by":"crossref","first-page":"e000243","DOI":"10.1136\/bmjgast-2018-000243","article-title":"Safety of dual biological therapy in Crohn\u2019s disease: a case series of vedolizumab in combination with other biologics","volume":"5","author":"Mao","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"key":"2025102819160075900_jjaf161-B94","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.dld.2024.08.055","article-title":"Effectiveness, safety, and cost of combination advanced therapies in inflammatory bowel disease","volume":"57","author":"McShane","year":"2025","journal-title":"Dig Liver Dis"},{"key":"2025102819160075900_jjaf161-B95","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s disease","volume":"69","author":"Miyatani","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2025102819160075900_jjaf161-B96","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40272-020-00396-1","article-title":"Combination of biological agents in moderate to severe pediatric inflammatory bowel disease: a case series and review of the literature","volume":"22","author":"Olbj\u00f8rn","year":"2020","journal-title":"Paediatr Drugs"},{"key":"2025102819160075900_jjaf161-B97","first-page":"757","article-title":"Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment","volume":"114","author":"Peter","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"2025102819160075900_jjaf161-B98","doi-asserted-by":"crossref","first-page":"jjaa149","DOI":"10.1093\/ecco-jcc\/jjaa149","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","volume":"15","author":"Privitera","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025102819160075900_jjaf161-B99","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/apt.16271","article-title":"Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy","volume":"53","author":"Privitera","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819160075900_jjaf161-B100","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1093\/ibd\/izab054","article-title":"Dual targeted therapy in patient with extensive Crohn\u2019s disease: different response at distinct location","volume":"27","author":"Privitera","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B101","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjx142","article-title":"Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy","volume":"12","author":"Roblin","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025102819160075900_jjaf161-B102","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1097\/PG9.0000000000000169","article-title":"Dual biologic therapy in an adolescent with Camurati-Engelmann disease and Crohn disease","volume":"3","author":"Sami","year":"2022","journal-title":"JPGN Rep"},{"key":"2025102819160075900_jjaf161-B103","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4292\/wjgpt.v8.i2.103","article-title":"Combination therapy for inflammatory bowel disease","volume":"8","author":"Sultan","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2025102819160075900_jjaf161-B104","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ejhpharm-2020-002437","article-title":"A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib","volume":"28","author":"Taberner Bonastre","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"2025102819160075900_jjaf161-B105","doi-asserted-by":"crossref","first-page":"1283251","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"key":"2025102819160075900_jjaf161-B106","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1111\/1346-8138.15283","article-title":"Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn\u2019s disease","volume":"47","author":"Vernero","year":"2020","journal-title":"J Dermatol"},{"key":"2025102819160075900_jjaf161-B107","doi-asserted-by":"crossref","first-page":"e00226","DOI":"10.14309\/crj.0000000000000226","article-title":"Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis","volume":"6","author":"Wang","year":"2019","journal-title":"ACG Case Rep J"},{"key":"2025102819160075900_jjaf161-B108","article-title":"Dual biologic therapy in moderate to severe pediatric inflammatory bowel disease: a retrospective study","volume":"10","author":"Wlaz\u0142o","year":"2022","journal-title":"Children (Basel)"},{"key":"2025102819160075900_jjaf161-B109","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jpn3.12179","article-title":"Combination biologic therapy in pediatric inflammatory bowel disease: safety and efficacy over a minimum 12-month follow-up period","volume":"79","author":"Wlazlo","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025102819160075900_jjaf161-B110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ibd\/izad064","article-title":"Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): a multicenter study from the pediatric IBD Porto Group of ESPGHAN","volume":"30","author":"Yerushalmy-Feler","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B111","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/ibd\/izae105","article-title":"Short-term use of upadacitinib in combination with biologic therapy for inducing clinical remission in patients with active inflammatory bowel disease","volume":"30","author":"Yin","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B112","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2016.66","article-title":"Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease","volume":"111","author":"Yzet","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025102819160075900_jjaf161-B113","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MEG.0000000000002886","article-title":"Combination vedolizumab and ustekinumab for refractory Crohn\u2019s disease after immune checkpoint inhibitors","volume":"37","author":"Zarker","year":"2025","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B114","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/00365521.2019.1597159","article-title":"Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis","volume":"54","author":"Ribaldone","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2025102819160075900_jjaf161-B115","doi-asserted-by":"crossref","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2025102819160075900_jjaf161-B116","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1007\/s10620-023-08130-w","article-title":"Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2025102819160075900_jjaf161-B117","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.12998\/wjcc.v11.i12.2621","article-title":"Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease","volume":"11","author":"McCormack","year":"2023","journal-title":"World J Clin Cases"},{"key":"2025102819160075900_jjaf161-B118","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ibd\/izx072","article-title":"Infliximab for Crohn\u2019s disease: more than 13 years of real-world experience","volume":"24","author":"Lichtenstein","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B119","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/MCG.0000000000001583","article-title":"Dual targeted therapy for the management of inflammatory bowel disease","volume":"55","author":"Haider","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"2025102819160075900_jjaf161-B120","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/ibd\/izaa279","article-title":"It takes two to make it right: dual biologic and small molecule therapy for treatment-refractory pediatric inflammatory bowel disease","volume":"27","author":"Geem","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819160075900_jjaf161-B121","doi-asserted-by":"crossref","first-page":"106935","DOI":"10.1016\/j.phrs.2023.106935","article-title":"Dual biological therapy and small molecules in pediatric inflammatory bowel disease","volume":"196","author":"Penagini","year":"2023","journal-title":"Pharmacol Res"},{"key":"2025102819160075900_jjaf161-B122","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11072004","article-title":"Dual biologic therapy for the treatment of pediatric inflammatory bowel disease: a review of the literature","volume":"11","author":"Wlaz\u0142o","year":"2022","journal-title":"J Clin Med"},{"key":"2025102819160075900_jjaf161-B123","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40272-023-00579-6","article-title":"Dual-targeted therapy in pediatric inflammatory bowel disease: a comprehensive review","volume":"25","author":"Yerushalmy-Feler","year":"2023","journal-title":"Paediatr Drugs"},{"key":"2025102819160075900_jjaf161-B124","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025102819160075900_jjaf161-B125","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025102819160075900_jjaf161-B126","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2025102819160075900_jjaf161-B127","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025102819160075900_jjaf161-B128","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/art.39262","article-title":"Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial","volume":"67","author":"van Vollenhoven","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025102819160075900_jjaf161-B129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2018.12.003","article-title":"Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"49","author":"Boleto","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025102819160075900_jjaf161-B130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"2025102819160075900_jjaf161-B131","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13555-017-0207-0","article-title":"The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review","volume":"7","author":"Sanchez","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025102819160075900_jjaf161-B132","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"2025102819160075900_jjaf161-B133","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2025102819160075900_jjaf161-B134","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-alpha and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025102819160075900_jjaf161-B135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2018Exit Strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025102819160075900_jjaf161-B136","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/ecco-jcc\/jjad181","article-title":"De-escalation of biologic treatment in inflammatory bowel disease: a comprehensive review","volume":"18","author":"Gisbert","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025102819160075900_jjaf161-B137","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission","volume":"8","author":"Burisch","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102819160075900_jjaf161-B138","first-page":"129","article-title":"Research progress in the combined treatment of ulcerative colitis","volume":"117","author":"Li","year":"2025","journal-title":"Rev Esp Enferm Dig"},{"key":"2025102819160075900_jjaf161-B139","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/j.gastro.2021.04.068","article-title":"Rational combination therapy to overcome the plateau of drug efficacy in inflammatory bowel disease","volume":"161","author":"Stalgis","year":"2021","journal-title":"Gastroenterology"},{"key":"2025102819160075900_jjaf161-B140","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1136\/annrheumdis-2017-212819","article-title":"Simultaneous inhibition of alpha4\/beta7 integrin and tumour necrosis factor-alpha in concomitant spondyloarthritis and inflammatory bowel disease","volume":"77","author":"Richard","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf161\/64200223\/jjaf161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf161\/64200223\/jjaf161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf161\/64200223\/jjaf161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:16:25Z","timestamp":1761693385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf161\/8246811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":140,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf161","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9]]},"article-number":"jjaf161"}}